Akbari Soheil, Arslan Nur, Senturk Serif, Erdal Esra
İzmir Biomedicine and Genome Center, İzmir, Turkey.
Department of Pediatric Gastroenterology and Metabolism, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey.
Front Cell Dev Biol. 2019 Dec 20;7:345. doi: 10.3389/fcell.2019.00345. eCollection 2019.
"" refers to all diagnostic and treatment strategies of diseases and conditions that cause liver failure directly or indirectly. Despite significant advances in the field of liver medicine in recent years, improved tools are needed to efficiently define the pathophysiology of liver diseases and provide effective therapeutic options to patients. Recently, organoid technology has been established as the state-of-the-art cell culture tool for studying human biology in health and disease. In general, organoids are simplified three-dimensional (3D) mini-organ structures that can be grown in a 3D matrix where the structural and functional aspects of real organs are efficiently recapitulated. The generation of organoids is facilitated by exogenous factors that regulate multiple signaling pathways and promote the self-renewal, proliferation, and differentiation of the cells to promote spontaneous self-organization and tissue-specific organogenesis. Newly established protocols suggest that liver-specific organoids can be derived from either pluripotent stem cells or liver-specific stem/progenitor cells. Today, robust and long-term cultures of organoids with the closest physiology to liver, in terms of cellular composition and function, open a new era in studying and understanding the disease pathology as well as high-throughput drug screening. Of note, these next-generation cell culture systems have immense potential to be further improved by genome editing and bioengineering technologies to foster the development of patient-specific therapeutic options for clinical applications. Here, we will discuss recent advances and challenges in the generation of human liver organoids and highlight emerging concepts for their potential applications in liver medicine.
“”指的是直接或间接导致肝衰竭的疾病和病症的所有诊断和治疗策略。尽管近年来肝脏医学领域取得了重大进展,但仍需要改进工具来有效界定肝脏疾病的病理生理学,并为患者提供有效的治疗选择。最近,类器官技术已成为研究健康和疾病状态下人类生物学的先进细胞培养工具。一般来说,类器官是简化的三维(3D)微型器官结构,可以在3D基质中生长,在其中能有效重现真实器官的结构和功能方面。类器官的生成由调节多种信号通路并促进细胞自我更新、增殖和分化以促进自发自我组织和组织特异性器官发生的外源性因子推动。新建立的方案表明,肝脏特异性类器官可以从多能干细胞或肝脏特异性干/祖细胞中获得。如今,就细胞组成和功能而言,具有与肝脏最接近生理学特征的类器官的强大且长期培养开启了研究和理解疾病病理学以及高通量药物筛选的新时代。值得注意的是,这些下一代细胞培养系统具有通过基因组编辑和生物工程技术进一步改进的巨大潜力,以促进针对临床应用的患者特异性治疗选择的开发。在此,我们将讨论人类肝脏类器官生成方面的最新进展和挑战,并强调其在肝脏医学中潜在应用的新兴概念。